Literature DB >> 20101209

Molecular pathogenesis of peripheral neuroblastic tumors.

I Janoueix-Lerosey1, G Schleiermacher, O Delattre.   

Abstract

Neuroblastoma (NB) is an embryonal cancer of the sympathetic nervous system observed in early childhood, characterized by a broad spectrum of clinical behaviors, ranging from spontaneous regression to fatal outcome despite aggressive therapies. NB accounts for 8-10% of pediatric cancers and 15% of the deaths attributable to malignant conditions in children. Interestingly, NB may occur in various contexts, being mostly sporadic but also familial or syndromic. This review focuses on recent advances in the identification of the genes and mechanisms implicated in NB pathogenesis. Although the extensive characterization of the genomic aberrations recurrently observed in sporadic NBs provides important insights into the understanding of the clinical heterogeneity of this neoplasm, analysis of familial and syndromic cases also unravels essential clues on the genetic bases of NB. Recently, the ALK gene emerged as an important NB gene, being implicated both in sporadic and familial cases. The identification of gene expression signatures associated with patient's outcome points out the potential of using gene expression profiling to improve clinical management of patients suffering from NB. Finally, based on recent observations integrating genomic analyses, biological data and clinical information, we discuss possible evolution/progression schemes in NB.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20101209     DOI: 10.1038/onc.2009.518

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  36 in total

Review 1.  Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma.

Authors:  Louis Chesler; William A Weiss
Journal:  Semin Cancer Biol       Date:  2011-09-21       Impact factor: 15.707

Review 2.  Neuroblastoma.

Authors:  Nadja C Colon; Dai H Chung
Journal:  Adv Pediatr       Date:  2011

3.  Activated ALK collaborates with MYCN in neuroblastoma pathogenesis.

Authors:  Shizhen Zhu; Jeong-Soo Lee; Feng Guo; Jimann Shin; Antonio R Perez-Atayde; Jeffery L Kutok; Scott J Rodig; Donna S Neuberg; Daniel Helman; Hui Feng; Rodney A Stewart; Wenchao Wang; Rani E George; John P Kanki; A Thomas Look
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

4.  The Transcription Regulator Krüppel-Like Factor 4 and Its Dual Roles of Oncogene in Glioblastoma and Tumor Suppressor in Neuroblastoma.

Authors:  Swapan K Ray
Journal:  For Immunopathol Dis Therap       Date:  2016

5.  The R1275Q neuroblastoma mutant and certain ATP-competitive inhibitors stabilize alternative activation loop conformations of anaplastic lymphoma kinase.

Authors:  Linda F Epstein; Hao Chen; Renee Emkey; Douglas A Whittington
Journal:  J Biol Chem       Date:  2012-08-29       Impact factor: 5.157

6.  Epigallocatechin gallate inhibits sphere formation of neuroblastoma BE(2)-C cells.

Authors:  Noriyuki Nishimura; Tri Budi Hartomo; Thi Van Huyen Pham; Myeong Jin Lee; Tomoto Yamamoto; Satoru Morikawa; Daiichiro Hasegawa; Hiroki Takeda; Keiichiro Kawasaki; Yoshiyuki Kosaka; Nobuyuki Yamamoto; Ikuko Kubokawa; Takeshi Mori; Tomoko Yanai; Akira Hayakawa; Yasuhiro Takeshima; Kazumoto Iijima; Masafumi Matsuo; Hisahide Nishio
Journal:  Environ Health Prev Med       Date:  2011-09-10       Impact factor: 3.674

Review 7.  Pharmacologic management of high-risk neuroblastoma in children.

Authors:  Veena R Ganeshan; Nina F Schor
Journal:  Paediatr Drugs       Date:  2011-08-01       Impact factor: 3.022

8.  Type III TGF-β receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma.

Authors:  Erik H Knelson; Angela L Gaviglio; Alok K Tewari; Michael B Armstrong; Karthikeyan Mythreye; Gerard C Blobe
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

9.  Autonomic neurocristopathy-associated mutations in PHOX2B dysregulate Sox10 expression.

Authors:  Mayumi Nagashimada; Hiroshi Ohta; Chong Li; Kazuki Nakao; Toshihiro Uesaka; Jean-François Brunet; Jeanne Amiel; Delphine Trochet; Teruhiko Wakayama; Hideki Enomoto
Journal:  J Clin Invest       Date:  2012-08-27       Impact factor: 14.808

10.  GLUT1 protein expression correlates with unfavourable histologic category and high risk in patients with neuroblastic tumours.

Authors:  Pramila Ramani; Alison Headford; Margaret T May
Journal:  Virchows Arch       Date:  2013-01-10       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.